Purple Biotech Ltd. (PPBT) Income Statement
PPBT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPPBT revenue and net income
PPBT profit margins
PPBT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PPBT quarterly EPS vs estimates
Purple Biotech beat the analyst EPS estimate in 2 of the last 7 quarters. Next report: November 13, 2026 (estimate $-2.88).
PPBT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $195,804 | $0 | $0 | $1.0M | $1.0M | $1.0M | $100,000 | $0 |
| Cost of revenue | $204,610 | $186,000 | $196,000 | $120 | $55 | $236,648 | $80 | $0 | $0 | — |
| Gross profit | −$204,610 | −$186,000 | −$196 | −$120 | −$55 | −$236,648 | $999,920 | $1.0M | $100,000 | — |
| Research & development | $3.7M | $7.6M | $17.0M | $16.3M | $11.8M | $7.3M | $2.3M | $5.3M | $4.6M | $4.2M |
| Sales, general & admin | $3.0M | $2.9M | $4.8M | $6.3M | $6.1M | $5.9M | $6.1M | $5.2M | $6.4M | $3.0M |
| Total operating expenses | $27.5M | $11.0M | $22.3M | $22.6M | $17.9M | $13.1M | $8.8M | $8.8M | $12.1M | $7.2M |
| Operating income | −$27.5M | −$11.0M | −$22.3M | −$22.6M | −$17.9M | −$13.3M | −$7.2M | −$7.8M | −$12.0M | −$7.2M |
| Interest income | $227,000 | $260,000 | $474,000 | $969,000 | $320,000 | $254,000 | $151,000 | $93,000 | $106,000 | $138,000 |
| Interest expense | $39,000 | $41,000 | $56,000 | $67,000 | $79,000 | $56,392 | $181,000 | $9,000 | $26,000 | $6,000 |
| Income before taxes | −$26.5M | −$7.3M | −$20.0M | −$21.8M | −$17.8M | −$28.9M | −$5.9M | −$5.6M | −$12.9M | −$12.1M |
| Income taxes | — | — | −$97,000 | $877,000 | $637,000 | −$15.7M | $216,000 | $207,000 | −$710,000 | $6,000 |
| Net income | −$26.4M | −$7.2M | −$19.9M | −$21.7M | −$18.4M | −$28.2M | −$5.8M | −$5.2M | −$12.2M | −$12.1M |
| EBITDA | −$26.2M | −$7.1M | −$19.7M | −$21.5M | −$17.5M | −$13.1M | −$6.1M | −$5.6M | −$12.9M | −$7.0M |
| EPS (diluted) | −$7.43 | −$62.52 | −$190.98 | −$105.07 | −$76.42 | −$0.07 | −$0.49 | −$30.11 | −$30.00 | −$2.90 |
| Gross margin | — | — | −0.1% | — | — | −23.7% | 100.0% | 100.0% | 100.0% | — |
| Operating margin | — | — | −11,374.1% | — | — | −1,333.2% | −715.6% | −782.6% | −11,966.0% | — |
| Net margin | — | — | −10,153.0% | — | — | −2,819.5% | −585.0% | −520.0% | −12,177.0% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $64,823 | $53,331 | $58,272 | $48,009 | $44,766 | $40,000 | $49,000 | $48,999 | — | $48,517 | $50,000 |
| Gross profit | — | −$64,823 | −$53,331 | −$58,272 | −$48,009 | −$44,766 | −$40,000 | −$49,000 | −$48,999 | — | −$48,517 | −$50,000 |
| Research & development | $702,000 | $1.2M | $1.8M | $587,000 | $553,000 | $760,000 | $458,000 | $1.3M | $2.4M | $3.4M | $5.3M | $4.6M |
| Sales, general & admin | $597,000 | $1.0M | $873,000 | $780,000 | $683,000 | $646,000 | $310,000 | $785,000 | $865,000 | $1.0M | $630,000 | $1.2M |
| Total operating expenses | $1.3M | $2.3M | $23.4M | $1.4M | $1.2M | $1.4M | $976,000 | $2.1M | $3.5M | $4.5M | $6.3M | $5.7M |
| Operating income | −$1.3M | −$2.3M | −$23.4M | −$1.4M | −$1.2M | −$1.4M | −$1.0M | −$2.1M | −$3.5M | −$4.5M | −$6.3M | −$5.7M |
| Interest income | $79,000 | $20,000 | $1,000 | $123,000 | $73,000 | $54,000 | $152,000 | $130,000 | $121,000 | $702,000 | $635,000 | $708,000 |
| Interest expense | $9,000 | $31,000 | $23,000 | $5,000 | $0 | $35,000 | $511,000 | $511,000 | $24,000 | $17,000 | $2.0M | $16,000 |
| Income before taxes | $441,000 | −$89,000 | −$23.6M | −$1.3M | −$1.1M | −$456,000 | −$415,000 | −$668,000 | −$2.4M | −$3.8M | −$4.9M | −$5.1M |
| Income taxes | — | — | — | — | — | — | — | — | −$9,999 | $683,000 | $1.2M | $689,000 |
| Net income | $441,000 | −$86,000 | −$23.5M | −$1.3M | −$1.1M | −$453,000 | −$410,000 | −$663,000 | −$2.4M | −$3.8M | −$4.9M | −$5.0M |
| EBITDA | $520,000 | $7,000 | −$23.6M | −$1.2M | −$1.0M | −$376,000 | −$886,000 | −$108,000 | −$2.3M | −$3.7M | −$6.3M | −$5.0M |
| EPS (diluted) | $1.07 | −$2.33 | −$6.16 | $2.90 | −$4.00 | −$0.17 | −$2.71 | −$13.67 | −$15.88 | −$30.26 | −$63.14 | −$42.02 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PPBT's financial statements (latest annual report filed March 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PPBT financial results
Purple Biotech reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $26.4 million. Diluted earnings per share came to −$7.43.
See the PPBT stock overview for the latest quote and news, or the PPBT chart for price history and technical indicators.
PPBT income statement FAQ
Does Purple Biotech have revenue?
Purple Biotech reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Purple Biotech profitable?
No. Purple Biotech reported a net loss of $26.4 million in fiscal 2025.
How much does Purple Biotech spend on research and development?
Purple Biotech spent $3.7 million on research and development in fiscal 2025.
What are Purple Biotech's earnings per share?
Purple Biotech earned $-7.43 per diluted share in fiscal 2025, compared with $-62.52 a year earlier.
When will Purple Biotech report its next earnings?
Purple Biotech is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Purple Biotech's fiscal year end?
Purple Biotech's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 19, 2026.